Table 1.
Main current active or recruiting clinical trials with CAR-T-cell therapies for AML.
| Status | Interventions | Phase | NCT Number | Locations |
|---|---|---|---|---|
| Recruiting | FLT3 CAR-T cells | Early Phase 1 | NCT04803929 | Zhejiang Provincial People’s Hospital, China |
| Recruiting | CLL-1 CAR-T cells | Phase 1 | NCT04219163 | Texas Children’s Hospital, Texas, United States |
| Recruiting | CD123/CLL1 CAR-T cells | Phase 2 Phase 3 |
NCT03631576 | Fujian Medical University Union Hospital, China |
| Recruiting | CD19 CAR-T cells | Phase 2 Phase 3 |
NCT04257175 | Chaim Sheba Medical Center, Israel |
| Recruiting | CLL-1, CD33 and/or CD123 CAR-T cells | Phase 1 Phase 2 |
NCT04010877 | Shenzhen Geno-immune Medical Institute, China |
| Recruiting | CLL1 CAR-T cells | Phase 1 Phase 2 |
NCT04884984 | The First Affiliated Hospital of Soochow University, China |
| Recruiting | CD38 CAR-T cells | Phase 1 Phase 2 |
NCT04351022 | The First Affiliated Hospital of Soochow University, China |
| Recruiting | CD33, CD38, CD56, CD123, CD117, CD133, CD34 and/or MUC-1 CAR-T cells | n/a | NCT03473457 | Southern Medical University Zhujiang Hospital, China |
| Recruiting | CD33 CAR-T cells | Phase 1 | NCT04835519 | Beijing Boren Hospital, China |
| Recruiting | CD33 CAR-T cells | Phase 1 Phase 2 |
NCT03971799 | Children’s Hospital of Los Angeles, California, United States [and others] |
| Recruiting | CD123 CAR-T cells | Phase 1 | NCT04014881 | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, China |
| Recruiting | CD19 CAR-T cells | Phase 1 Phase 2 |
NCT03896854 | The First Affiliated Hospital of Soochow University, China |
| Recruiting | B7-H3 CAR-T cells | n/a | NCT04692948 | Anhui Provincial Hospital, China |
| Recruiting | CD44v6 CAR-T cells | Phase 1 Phase 2 |
NCT04097301 | IRCCS San Raffaele, Italy IRCCS Ospedale Pediatrico Bambino Gesù, Italy |
| Recruiting | CD123 CAR-T cells | Phase 1 | NCT04318678 | St. Jude Children’s Hospital, Tennessee, United States |
| Recruiting | Allogeneic CD123 CAR-T cells | Phase 1 | NCT03190278 | University of California, San Francisco (UCSF)-Helen Diller Family Comprehensive Cancer Center, California, United States [and others] |
| Recruiting | CD123 CAR-T cells | Phase 1 Phase 2 |
NCT04272125 | Chongqing University Cancer Hospital, China |
| Recruiting | Allogeneic CD19 CAR-γδT cells | n/a | NCT04796441 | Hebei yanda Ludaopei Hospital, China |
| Recruiting | CLL1 CAR-T cells | Early Phase 1 | NCT04923919 | No.212 Daguan Road, Xishan District, China |
| Recruiting | CD123 CAR-T cells | Phase 1 Phase 2 |
NCT04265963 | 920th Hospital of Joint Logistics Support Force, China |
| Recruiting | CLL-1 CAR-T cells | Phase 1 | NCT04789408 | Washington University School of Medicine, Missouri, United States [and other] |
| Recruiting | CD19, CD20, CD22, CD10, CD33, CD38, CD56, CD117, CD123, CD34, or MUC-1 CAR-T cells +/− peptide-specific DCs | Phase 1 | NCT03291444 | Zhujiang Hospital, Southern Medical University, China |
| Recruiting | CD123 CAR-T cells (autologous vs allogeneic) |
Phase 1 | NCT02159495 | City of Hope Medical Center, California, United States |
| Recruiting | CD7 CAR-T cells | Phase 1 Phase 2 |
NCT04762485 | The First Affiliated Hospital of Soochow University, China |
| Active, not recruiting | CD123 CAR-T cells | Phase 1 | NCT03766126 | University of Pennsylvania, Pennsylvania, United States |
| Recruiting | CD123 CAR-T cells | Phase 1 | NCT04678336 | Children’s Hospital of Philadelphia, Pennsylvania, United States |
| Recruiting | CD123 UniCAR-T cells | Phase 1 | NCT04230265 | Universitätsklinikum Ulm, Germany [and others] |
| Recruiting | CD7 CAR-T cells | Phase 1 Phase 2 |
NCT04033302 | Shenzhen Geno-immune Medical Institute, China |
| Recruiting | NKG2D Ligands CAR-T cells | Phase 1 | NCT04167696 | Mayo Clinic Cancer Center, Florida, United States [and others] |